世界におけるペプチド治療薬パイプラインインサイト：環状ペプチド、ポリペプチド、糖ペプチド、リポペプチド、ペプチドワクチン等...市場調査レポートについてご紹介

1. Introduction to Peptides

2. Mechanism of Peptide Therapeutics

3. Global Peptide Therapeutics Market Overview
3.1 Current Market Scenario
3.2 Peptide Pipeline Overview

4. Global Peptide Therapeutics Market Dynamics
4.1 Market Growth Drivers
4.2 Commercialization Challenges

5. Global Peptide Therapeutics Market Future Prospects

6. Insulin Pipeline by Company, Indication & Phase
6.1 Phase Research to till Registered
6.2 Marketed

7. Peptides Pipeline by Company, Indication & Phase
7.1 Phase Research to till Registered
7.2 Marketed

8. Cyclic Peptides Pipeline by Company, Indication & Phase
8.1 Phase Research to till Preregistration
8.2 Marketed

9. Polypeptide Pipeline by Company, Indication & Phase
9.1 Phase Research to till Phase-III
9.2 Marketed

10. Glycopeptide Pipeline by Company, Indication & Phase
10.1 Phase Research to till Registered
10.2 Marketed

11. Lipopeptides Pipeline by Company, Indication & Phase
11.1 Phase Research to till Phase-III
11.2 Phase: Marketed

12. Oligopeptide Pipeline by Company, Indication & Phase
12.1 Phase Research to till Preregistration
12.2 Marketed

13. Depsi Peptide Pipeline by Company, Indication & Phase
13.1 Phase Research to till Phase-III
13.2 Marketed

14. Neuropeptide Pipeline by Company, Indication & Phase
14.1 Phase Preclinical to till Phase-II/III
14.2 Marketed

15. Dipeptides Pipeline by Company, Indication & Phase
15.1 Phase Preclinical to till Phase-III
15.2 Marketed

16. Natriuretic Peptide Pipeline by Company, Indication & Phase
16.1 Phase Preclinical to till Phase-III

17. Opioid Peptide Pipeline by Company, Indication & Phase
17.1 Phase Preclinical to till Preregistration
17.2 Marketed

18. Peptide Vaccine Pipeline by Company, Indication & Phase
18.1 Phase Preclinical to till Phase-III

19. Antimicrobial Cationic Peptide Pipeline by Company, Indication & Phase
19.1 Phase Preclinical to till Phase-III

20. Multiple Peptides Pipeline by Company, Indication & Phase
20.1 Phase Preclinical to till Registered
20.2 Marketed

21. Competitive Landscape
21.1 Amgen
21.2 Amylin Pharmaceuticals
21.3 Corden Pharma (Peptisyntha)
21.4 GlaxoSmithKline
21.5 Ipsen
21.6 Lonza
21.7 Merck
21.8 PeptiDream
21.9 Roche
21.10 Sanofi

Figure 1-1: Components of Peptide
Figure 1-2: Features of Peptide Therapeutics
Figure 2-1: Benefits of Peptide Modifications
Figure 2-2: Benefits of Computational Methods
Figure 2-3: Different Types of Peptide Formulation Vehicles
Figure 2-4: Mechanism of Vibativ
Figure 2-5: Mechanism of Liraglutide
Figure 2-6: Mechanism of Goserelin
Figure 2-7: Formulation of Orally Administrated Peptide Therapeutics
Figure 3-1: Global Peptide Market (US$ Billion), 2013-2018
Figure 3-2: Insulin Pipeline by Phase (%), 2015
Figure 3-3: Insulin Pipeline by Phase (Number), 2015
Figure 3-4: Peptides Pipeline by Phase (%), 2015
Figure 3-5: Peptides Pipeline by Phase (Number), 2015
Figure 3-6: Cyclic Peptide Pipeline by Phase (%), 2015
Figure 3-7: Cyclic Peptide Pipeline by Phase (Number), 2015
Figure 3-8: Polypeptide Pipeline by Phase (%), 2015
Figure 3-9: Polypeptide Pipeline by Phase (Number), 2015
Figure 3-10: Glycopeptide Pipeline by Phase (%), 2015
Figure 3-11: Glycopeptide Pipeline by Phase (Number), 2015
Figure 3-12: Lipopeptide Pipeline by Phase (%), 2015
Figure 3-13: Lipopeptide Pipeline by Phase (Number),2014
Figure 3-14: Oligopeptide Pipeline by Phase (%), 2015
Figure 3-15: Oligopeptide Pipeline by Phase (Number), 2015
Figure 3-16: Depsi Peptide Pipeline by Phase (%), 2015
Figure 3-17: Depsi Peptide Pipeline by Phase (Number), 2015
Figure 3-18: Neuropeptide Pipeline by Phase (%), 2015
Figure 3-19: Neuropeptide Pipeline by Phase (Number), 2015
Figure 3-20: Dipeptide Pipeline by Phase (%), 2015
Figure 3-21: Dipeptide Pipeline by Phase (Number), 2015
Figure 3-22: Natriuretic Peptide Pipeline by Phase (%), 2015
Figure 3-23: Natriuretic Peptide Pipeline by Phase (Number), 2015
Figure 3-24: Opioid Peptide Pipeline by Phase (%), 2015
Figure 3-25: Opioid Peptide Pipeline by Phase (Number), 2015
Figure 3-26: Peptide Vaccine Pipeline by Phase (%), 2015
Figure 3-27: Peptide Vaccine Pipeline by Phase (Number), 2015
Figure 3-28: Antimicrobial-Cationic-Peptide Pipeline by Phase (%), 2015
Figure 3-29: Antimicrobial-Cationic-Peptide Pipeline by Phase (Number), 2015
Figure 3-30: Multiple Peptide Pipeline by Phase (%), 2015
Figure 3-31: Multiple Peptide Pipeline by Phase (Number), 2015
Figure 4-1: Global Peptide Therapeutics Market Growth Drivers
Figure 4-2: Global Peptide Therapeutics Market Commercialization Challenges